The company’s biggest deal in specialty drugsgives it rights to the lead candidate deuruxolitinib, a drug that is being portrayed as a “potential best-in-class” treatment for alopecia areata, an autoimmune disorder that leads to hair loss. What are the factors that prompted Sun Pharma to go for this big bet?
Sun Pharmaceutical Industries is scaling new heights. After a setback in the US generic-drugs business, India’s largest drugmaker has gradually moved up the value chain and built a sizeable specialty-drugs business over the last few years. Dilip Shanghvi, founder and managing director of Sun Pharma, with his astute sense of business and passion for science, has dodged critics and patiently created a specialty-drugs portfolio through a string of
- FONT SIZE
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Login to read the full story.
Unlock your 30 days free access
to ETPrime now.
Login to Unlock
*No card details required
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Comment & Engage with ET Prime community
Exclusive invites to Virtual Events with Industry Leaders
A trusted team of Journalists & Analysts who can best filter signal from noise